feedback

Provider Statements

This continuing medical education activity is provided by

This continuing pharmacy education activity is provided by

Support Statement

This activity is supported by an educational grant from ViiV Healthcare.

Activity Chair

Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:
Consulting Fee: AbbVie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline/ViiV, Janssen, Merck
Contracted Research: (Paid to Institution) Bristol-Myers Squibb, Gilead, GlaxoSmithKline/ViiV, Merck


Planning Committee

Eric S. Daar, MD*
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Torrance, CA

*Author for this activity.

Disclosures:
Consulting Fee: (Paid to Institution) Bristol-Myers Squibb, Gilead, Janssen, Merck, Teva, ViiV
Contracted Research: (Paid to Institution) Gilead, Merck, ViiV


Richard A. Elion, MD
Associate Clinical Professor of Medicine
George Washington University School of Medicine
Co-Director, DC Dept of Health STD Research Program
Washington, DC

Disclosures:
Consulting Fee: Gilead, ViiV
Speakers Bureau: Gilead, Janssen, Merck, ViiV
Other Disclosure: Advisor: Gilead, Merck, ViiV. Expert Witness: Gilead


Joseph J. Eron, Jr., MD
Professor of Medicine, Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC

Disclosures:
Consulting Fee: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, ViiV
Contracted Research: (Paid to Institution) Bristol-Myers Squibb, Gilead, Janssen, ViiV

External Reviewer

Rebecca A. Clark, MD
Disclosures: No relevant financial relationships to disclose.

Pharmacy Reviewer

Jennifer Frederick, PharmD, BCPS
Disclosures: No relevant financial relationships to disclose.

National Jewish Health and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at National Jewish Health and Vindico Medical Education, Offices of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education and Accreditation Council for Pharmacy Education’s Standards for Commercial Support, all CME/CPE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, authors, and reviewers, involved in the development of CME/CPE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME/CPE activity content over which the individual has control. Relationship information appears above.

Activity Details

Credit Type: AMA PRA Category 1 Credit
ACPE Continuing Education Credit
Credit Amount: 0.25
Release Date: December 30, 2016
Expiration Date: December 30, 2017
Estimated Time to Complete Activity: 15 minutes
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-9999-16-026-H02-P, effective 12/30/2016. This is a knowledge-based activity and there is no fee to attend.

This enduring material is approved for 1 year from the date of original release, December 30, 2016 to December 30, 2017.

How to Participate in this Activity and Obtain CME/CPE Credit

To participate in this CME/CPE activity, you must read the objectives, answer the pretest questions, read the article, complete the posttest, and fill-in the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, National Jewish Health will issue an AMA PRA Category 1 Credit(s)™ Certificate or Vindico Medical Education will issue a Certificate of Pharmacy Credit.

Overview

With the availability of highly effective antiretroviral agents and combinations, treatment-experienced HIV patients with extensive drug resistance now have multiple options for suppressive therapy. However, advances in treatment and management also create new challenges for clinicians who must be knowledgeable about the expanding treatment armamentarium and interpretation of various resistance tests, as well as complex issues of pharmacokinetics and drug interactions. This interactive case-based activity will review the management of a patient with virologic failure to first-line integrase inhibitor therapy.

Target Audience

The intended audience for this activity is infectious disease physicians, HIV treaters, pharmacists, and other health care professionals involved in the treatment of patients with HIV.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Compare and contrast the resistance profiles of available and emerging HIV treatment regimens.
  • Evaluate the effective use of switch strategies and NRTI-sparing regimens that have demonstrated a low risk of virological failure in patients who would benefit from treatment alteration.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2016 Vindico Medical Education®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of National Jewish Health and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of National Jewish Health and Vindico Medical Education. Neither National Jewish Health, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CPE Questions?

Contact us at CME@Vindicocme.com

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.